Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
- Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
- Aldeyra receives orphan designation for ADX-2191 from EMA
- FDA Accepts Aldeyra’s Reproxalap Application for Review
- Aldeyra announces FDA acceptance for review of reproxalap NDA